
APGE Stock Forecast & Price Target
APGE Analyst Ratings
Bulls say
Apogee Therapeutics Inc. is positioned strongly in the biotechnology sector due to its approach of developing monoclonal antibodies (mAbs) targeting established mechanisms for diseases with high unmet need, such as atopic dermatitis and chronic obstructive pulmonary disease. The company anticipates a significant market expansion within the atopic dermatitis sector, projected to grow to approximately $30 billion by 2035, supported by reduced competition and increased validation of its products. Furthermore, success in the upcoming Phase 2 clinical trial of the candidate APG777 is expected to not only enhance the company's product portfolio but also potentially lead to the development of a best-in-class monotherapy, creating substantial financial upside.
Bears say
Apogee Therapeutics faces substantial risks to its stock performance, primarily due to potential market entry of biosimilars like REGN/SAN-PAR's Dupixent before 2035-37, which may erode its competitive positioning. The biotechnology company's clinical programs, specifically APG777, carry uncertainties surrounding their safety, efficacy, and tolerability compared to existing treatments, which could lead to disappointing trial results and unforeseen development delays. Furthermore, the atopic dermatitis market remains largely under-penetrated, with only about 10% of eligible patients currently receiving systemic treatments, indicating a challenging market landscape that may hinder Apogee's growth potential.
This aggregate rating is based on analysts' research of Apogee Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
APGE Analyst Forecast & Price Prediction
Start investing in APGE
Order type
Buy in
Order amount
Est. shares
0 shares